NDA 212614 · Boehringer Ingelheim
Trijardy Xr
Empagliflozin, Linagliptin, Metformin Hydrochloride · Oral · Sodium-Glucose Cotransporter 2 Inhibitor; Dipeptidyl Peptidase 4 Inhibitor
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 27, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
544
123 Phase 3, 99 recruiting
FAERS reports
124
45 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...
What it is approved for
From the label in effect Aug 24, 2026.
TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease [see Clinical Studies (14.2) ] . TRIJARDY XR is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 ) Limitations of Use TRIJARDY XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions (5.2) ] . TRIJARDY XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRIJARDY XR [see Warnings and Precautions (5.3) ].
Mechanism: TRIJARDY XR TRIJARDY XR contains: empagliflozin, a SGLT2 inhibitor, linagliptin, a DPP-4 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Linagliptin Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 2020 Supplement 4 · Efficacy LetterLabel
- Jan 27, 2020 Original approval · Type 4 - New Combination LabelLetterReview
4 products under this application
- TRIJARDY XR · EMPAGLIFLOZIN 25MG; LINAGLIPTIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
- TRIJARDY XR · EMPAGLIFLOZIN 10MG; LINAGLIPTIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
- TRIJARDY XR · EMPAGLIFLOZIN 12.5MG; LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
- TRIJARDY XR · EMPAGLIFLOZIN 5MG; LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Empagliflozin" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordPivotal-lookingRecruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT06642272 · 17,200 participants (planned) · Start Oct 10, 2024 · Primary completion Dec 31, 2028
Drug: Empagliflozin 10 MG; Dapagliflozin 10 MG · For: Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 12 sites in all
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06531824 · 8,371 participants · Start Aug 30, 2024 · Primary completion Dec 31, 2026
Drug: BI 690517; Placebo matching BI 690517 and 1 more · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Beverly Hills, California · 562 sites in all
- BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01131676 · 7,064 participants · Start Jul 2010 · Primary completion Apr 2015
Drug: BI 10773 low dose; Placebo BI 10773 high dose and 4 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 615 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03594110 · 6,609 participants · Start Jan 31, 2019 · Primary completion Jul 5, 2022
Drug: Empagliflozin; Matching placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Mesa, Arizona; San Diego, California · 240 sites in all
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04509674 · 6,522 participants · Start Dec 16, 2020 · Primary completion Nov 5, 2023
Drug: Empagliflozin; Placebo · For: Myocardial Infarction
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 439 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased20
- off label use11
- fatigue10
- diarrhoea7
- headache6
- nausea6
- vomiting6
- weight decreased6
- dizziness5
- drug ineffective5
- glycosylated haemoglobin increased5
- decreased appetite4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 45 |
| 2022 | 23 |
| 2023 | 17 |
| 2024 | 14 |
| 2025 | 10 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trijardy XR (Empaglifloz/Linaglip/Metformin)
2024 spending
$99.1M
Beneficiaries
21,512
112,533 claims
Per beneficiary
$4,609
$14.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,450,472 |
| 2021 | $17,542,710 |
| 2022 | $43,294,714 |
| 2023 | $76,136,040 |
| 2024 | $99,142,501 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Empagliflozin in Patients with Chronic Kidney Disease.
Herrington WG, Staplin N, Wanner C, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, et al. · Nat Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD, Butler J, Filippatos G, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Agarwal R, Green JB, Heerspink HJL, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.